Veeda Clinical Research Limited
₹428▼4.46%(20.00)
About the company
Veeda Clinical Research Limited is one of India's leading independent Contract Research Organizations (CROs), providing comprehensive clinical research services to pharmaceutical, biotechnology, and healthcare companies worldwide. Established in 2004, the company has built a strong reputation for delivering high-quality, science-driven research solutions that support the development of safe and effective medicines while meeting global regulatory standards.
Veeda offers a full range of end-to-end clinical research services, including pre-clinical support, early-phase and late-phase clinical trials, bioanalytical services, and clinical data management. Its integrated business model enables clients to efficiently manage the drug development process from research through regulatory approval. With a strong focus on quality, regulatory compliance, innovation, and timely project execution, Veeda Clinical Research Limited continues to play an important role in advancing clinical research and helping bring new healthcare therapies to patients across the globe.
Fundamentals
Valuation
| Metric | Value |
|---|---|
| 52 week high | ₹475 |
| 52 week low | ₹428 |
| P/B ratio | 3.26 |
| Debt to equity | 0.47 |
| ROE (%) | -7.77% |
| Book value | ₹131.38 |
| Face value | ₹2 |
52 week high
52 week low
P/B ratio
Debt
Equity
| Metric | Value |
|---|---|
| 52 week high | ₹475 |
| 52 week low | ₹428 |
| P/B ratio | 3.26 |
| Debt | 32.0% of capital |
| Equity | 68.0% of capital |
Registry
| Metric | Value |
|---|---|
| PAN number | AACCC3633Q |
| ISIN number | INE01HQ01026 |
| CIN | U73100GJ2004PLC044023 |
Figures in cr ·
Financials
| P&L Statement | 2025Latest | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 610 | 388 | 409 | 288 | 196 | 151 |
| EBITDA | 125 | 53 | 103 | 62 | 67 | 20 |
| OPM | 20.49 | 13.66 | 25.18 | 21.53 | 34.18 | 13.25 |
| PBT | -66 | 3.3 | 59 | 65 | 85 | 0.89 |
| PAT | -67 | -0.3 | 42 | 50 | 63 | -0.01 |
| EPS | -10.19 | -0.04 | 8 | 9.46 | 17.6 | 0 |
Shareholding Pattern
Basil Private Limited
Bondway Investment Inc.
Others
| Holder | Percentage |
|---|---|
| Basil Private Limited | 33.83% |
| Bondway Investment Inc. | 19.20% |
| Others | 46.97% |
Leadership
Frequently asked questions
Common questions on Veeda Clinical Research Limited—tap a row to read the answer.
Q.1What does Veeda Clinical Research Limited do?
Veeda Clinical Research Limited is a leading Indian Contract Research Organization (CRO) that provides end-to-end clinical research services to pharmaceutical, biotechnology, and healthcare companies. Its services include early and late-phase clinical trials, bioanalytical testing, clinical data management, and regulatory support to help bring new medicines to market efficiently
Q.2What should investors consider before investing in Veeda Clinical Research Limited?
Before investing, it is important to evaluate the company's financial performance, research capabilities, client base, regulatory compliance, management team, growth strategy, industry outlook, and valuation. Reviewing these factors can help investors make a well-informed investment decision.
Q.3What are the risks of investing in Veeda Clinical Research Limited unlisted shares?
Like any unlisted investment, Veeda Clinical Research Limited shares carry certain risks, including limited liquidity, price volatility, lower public disclosure, and uncertainty regarding future listing plans. Investors should carefully assess these risks and align them with their investment goals.
Q.4Does Veeda Clinical Research Limited have any IPO plans?
As of now, there is no officially confirmed IPO date for Veeda Clinical Research Limited. Any future plans for a public listing are expected to be announced through official company communications and applicable regulatory filings.
Q.5. How is the price of Veeda Clinical Research Limited unlisted shares determined?
The price of Veeda Clinical Research Limited unlisted shares depends on several factors, including the company's financial performance, business growth, client portfolio, investor demand, industry trends, market sentiment, and recent transactions in the unlisted shares market.
Unlisted Trending shares
High-demand unlisted opportunities currently available for trade.
MARKET INSIGHTS & UPDATES
Read the latest updates, investment ideas, and market insights designed to help investors better understand unlisted and pre-IPO opportunities.

NSE IPO 2026: Dates, Allotment & Listing Details
The much-awaited NSE IPO is set to make a major market debut in September 2026. As per the announced schedule, the IPO will open on 21 September and close on 23 September 2026, followed by share allotment on 24 September and listing on 28 September 2026. With strong investor interest and NSE’s position as one of India’s leading market institutions, the IPO is expected to attract significant attention. Here’s a quick look at the NSE IPO 2026 timeline and important dates investors should know.

Upcoming IPOs in 2026: NSE, Rentomojo, Manipal & Pranav Guide
Four major 2026 IPOs: NSE, Manipal Payment, Rentomojo, Pranav Constructions. For pre-IPO investors, these mark critical transitions from private to public valuations. Conduct due diligence before investing.

Purple Style Labs: From Unlisted Shares to IPO - A Price Journey Worth Noticing
Purple Style Labs is making headlines as it moves from the unlisted market towards its IPO. With its unlisted shares trading around ₹500–₹525 and an IPO price band of ₹546–₹575, the price journey offers an interesting look at how private-market and IPO valuations can differ.

Muthoot FinCorp Unlisted Shares: Q1FY27 Profit Surges to ₹705 Cr | Fundamentals & IPO
Muthoot FinCorp's Q1FY27 profit surged to ₹705.48 crore as the company moves toward a proposed ₹3,000-crore IPO. Here's a look at its financial performance, valuation metrics, asset quality and key fundamentals.

From Debt to Debt-Free: How API Holdings Used Thyrocare to Reshape Its Balance Sheet
API Holdings has repaid ₹1,050 crore of debt by monetising a 9.90% stake in Thyrocare while retaining 51.02% control. Here's how the move reshapes its balance sheet and what it means going forward.

Pre IPO Shares in India: Price, How to Buy & Complete Guide
Learn what Pre IPO Shares are, how their prices are determined, how to buy them in India, and what investors should check before investing in unlisted companies.
